[Vaccination of cats against infection with feline leukemia virus (FeLV): first recombinant vaccine and the effect of a pre-existing infection with feline immunodeficiency virus (FIV)].
A new recombinant FeLV vaccine was evaluated in 30 specified pathogen-free cats 10 months of age cats. The vaccine consisted of the non-glycosylated FeLV envelope protein p45, aluminium hydroxide and a saponin adjuvant. The cats (n = 18) were vaccinated twice intramuscularly, 3 weeks apart. All animals were challenged intraperitoneally with FeLV subgroup A, 18 weeks later. While 94% of the vaccinated cats showed no viraemia or were only transiently viraemic, 80% of the non-vaccinated animals became persistently viraemic within 2 to 3 weeks. In our hands the preventable fraction of the vaccine was 93%. In order to determine the effect of a pre-existing infection with feline immunodeficiency virus on the efficacy of vaccination, 50% of the cats were previously infected with FIV. The infected cats were protected to the same degree as the non-infected animals. With prolonged duration of FIV infection the probability increases, that the immune system of the cat will fail and clinical signs will appear. In order to observe a state of possible immunodeficiency, an accurate clinical examination of every cat prior to vaccination seems of major importance.
Hofmann-Lehmann
R
R
Departement für Innere Veterinärmedizin, Universität Zürich.
Aubert
A
A
Wolfensberger
C
C
Cronier
J
J
Lutz
H
H
D000818:Animals; D002415:Cats; D016181:Feline Acquired Immunodeficiency Syndrome / Q000276:immunology*; D016089:Immunodeficiency Virus, Feline / Q000276:immunology*; D005256:Leukemia Virus, Feline / Q000276:immunology*; D016582:Leukemia, Feline / Q000517:prevention & control*; D008297:Male; D013047:Specific Pathogen-Free Organisms; D014611:Vaccination / Q000662:veterinary; D014614:Vaccines, Synthetic; D014765:Viral Vaccines
D014614:Vaccines, Synthetic; D014765:Viral Vaccines
Impfung von Katzen gegen die Infektion mit dem felinen Leukämievirus (FeLV): Erster rekombinanter Impfstoff und Einfluss einer vorbestehenden Infektion mit dem felinen Immunschwächevirus (FIV).